TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$56.25-6.02%
Price as of Jul 20, 2026
TARS capital
Tarsus Pharmaceuticals, Inc. capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- 0.25x
- Net debt / equity
- -0.04x
- Debt / assets
- 0.15x
- Debt / EBITDA
- -2.21x
- Net debt / EBITDA
- 0.34x
Liquidity & coverage
- Current ratio
- 3.74x
- Quick ratio
- 3.71x
- Cash ratio
- 2.71x
- Interest coverage
- -5.94x
- EBITDA / interest
- -4.70x
- Working capital
- $393.7M
Cash & dividend
- FCF / debt
- -0.36x
- Cash flow / debt
- -0.19x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.